钙泊三醇倍他米松软膏与卡泊三醇软膏联合NB-UVB治疗稳定期寻常性银屑病疗效比较

目的观察钙泊三醇倍他米松软膏和卡泊三醇软膏分别联合窄谱中波紫外线(NB-UVB)照射治疗寻常性银屑病的疗效与安全性。方法将入选的60例患者随机分为2组,各30例。治疗组每晚用钙泊三醇倍他米松软膏外搽皮损1次,对照组每日早、晚分别予卡泊三醇软膏外搽皮损1次,且两组同时予NB-UVB照射治疗,3次/周。两组患者的疗程均为4周。分别于治疗过程中每周观察1次疗效。结果治疗2周时,治疗组有效率(33.33%)高于对照组(10.00%),差异有统计学意义(P<0.05)。治疗4周时,治疗组有效率和对照组差异不显著(P>0.05)。主要不良反应为瘙痒和毛囊炎。结论钙泊三醇倍他米松软膏或卡泊三醇软膏联合NB-UVB治疗寻常性银屑病均安全有效,但钙泊三醇倍他米松软膏起效快于卡泊三醇软膏。     

钙泊三醇倍他米松软膏联合中药浴治疗寻常性斑块状银屑病疗效观察

目的观察钙泊三醇倍他米松软膏联合中药浴治疗寻常性斑块状银屑病的临床疗效及不良反应。方法将93例寻常性斑块状银屑病患者随机分为试验组和对照组,均外用钙泊三醇倍他米松软膏每日1次;试验组同时给予中药方剂洗浴每日1次,对照组使用婴儿沐浴液洗浴每日1次,两组均4周为1个疗程,分别于2、4周时观察疗效。结果治疗结束后,试验组有效率为86.96%,对照组有效率为70.21%,两组比较差异有统计学意义(χ2=3.86,P0.05)。两组患者均无严重不良反应。结论钙泊三醇倍他米松软膏联合中药浴治疗寻常性斑块状银屑病疗效好,能很快缓解皮损症状,是一种安全有效的治疗方法。     

卡泊三醇软膏联合口服中药治疗寻常性斑块状银屑病的临床疗效观察

目的 评价单纯外用卡泊三醇软膏和外用卡泊三醇软膏联合口服中药治疗对寻常性斑块状银屑病的疗效.方法 60例患者随即分成单纯外用卡泊三醇软膏组和外用卡泊三醇软膏联合口服中药组.疗程为12周.两组患者分别于治疗后进行临床疗效评估.结果 两组于第8周以后皮损PASI评分差异有统计学意义(P<0.05).治疗结束时,单纯西药组的有效率为73.3%,中西药联合组的有效率为93.3%,两组比较差异有统计学意义(P<0.05).结论 外用卡泊三醇软膏联合口服中药治疗寻常性斑块状银屑病优于单纯外用卡泊三醇软膏治疗.     

吡硫翁锌气雾剂联合钙泊三醇倍他米松软膏序贯治疗斑块型银屑病的观察

目的观察吡硫翁锌气雾剂联合钙泊三醇倍他米松软膏序贯治疗斑块型银屑病的疗效以及安全性。方法 182例斑块状银屑病患者随机分为观察组和对照组,观察组90例应用吡硫翁锌气雾剂联合钙泊三醇倍他米松软膏外用治疗,对照组92例单用钙泊三醇倍他米松软膏外用治疗;两组疗程均为4周。结果观察组有效率为83.3%;对照组有效率为52.2%;两组比较差异均有统计学意义(P0.05)。结论应用吡硫翁锌气雾剂联合钙泊三醇倍他米松软膏序贯治疗银屑病起效快、副作用小。     

钙泊三醇倍他米松软膏治疗斑块状银屑病疗效评价

目的:评价钙泊三醇倍他米松软膏治疗斑块状银屑病的临床疗效。方法:治疗组(70例)给予钙泊三醇倍他米松软膏外用,对照组(56例)给予钙泊三醇软膏外用和5%松馏油软膏封包。结果:6周后治疗组有效率为88.57%,对照组有效率为75.00%,不良反应发生率分别为10.00%和23.75%,差异均有统计学意义(均P0.05)。结论:钙泊三醇倍他米松软膏外用治疗斑块状银屑病有效且相对安全。     

钙泊三醇倍他米松软膏联合NB-UVB治疗寻常型银屑病的效果观察

目的观察钙泊三醇倍他米松软膏+窄谱中波紫外线(NB-UVB)对寻常型银屑病(PV)患者皮损程度(PASI)评分的影响。方法选取我院76例PV患者(2018年4月～2019年3月),按照简单随机化分组,每组各38例,对照组采用钙泊三醇倍他米松软膏治疗,观察组采用钙泊三醇倍他米松软膏+NB-UVB治疗。比较两组疗效、治疗前后PASI评分及白介素-6(IL-6)、IL-8水平。结果观察组总有效率(94.74%)高于对照组(78.95%),差异有统计学意义(P 0.05);治疗后观察组PASI评分及IL-6、IL-8水平低于对照组,差异有统计学意义(P 0.05)。结论钙泊三醇倍他米松软膏加NB-UVB治疗PV具有显著效果,可减轻机体炎症反应,改善皮损程度。     

钙泊三醇倍他米松乳膏与卡泊三醇软膏序贯治疗银屑病

目的:观察钙泊三醇倍他米松乳膏与卡泊三醇软膏序贯治疗银屑病患者的疗效及安全性。方法:将90例斑块状寻常性银屑病患者随机分为3组,第一组:外用钙泊三醇倍他米松乳膏4周(每日1次)+钙泊三醇倍他米松乳膏与卡泊三醇软膏交替使用2周(均每日1次,2种交替)+卡泊三醇软膏6周(每日1次);第二组:外用钙泊三醇倍他米松软膏6周+卡泊三醇软膏6周(均每日1次);第三组:外用卡泊三醇软膏12周(每日2次)。结果:3组患者治疗4、6、12周后银屑病皮损面积和严重程度指数(PASI)评分分别与各组治疗前比较,差异均有统计学意义(P均0.05)。第一组与第二组疗效均优于第三组,差异均有统计学意义(P均0.05),但第一组与第二组疗效比较,差异无统计学意义(P0.05)。结论:序贯疗法起效快且疗效优,为患者节省医疗开支并减少糖皮质激素的不良反应。     

卡泊三醇软膏两种不同用法治疗轻中度斑块状银屑病的疗效观察

目的:观察卡泊三醇软膏分别按疗程和症状两种不同用药方法治疗轻中度斑块状银屑病的疗效及安全性.方法:斑块状银屑病患者60例,随机分为疗程治疗组及症状治疗组,每组30例,前者给予卡泊三醇软膏每日2次,共8周;后者给予卡泊三醇软膏每日2次,4周症状改善后改为每日1次,共8周,治疗前及治疗后第2、4、8周分别进行PASI评分,治疗前及治疗结束时测血钙浓度,判定疗效及记录不良反应.结果:经过8周观察,疗程治疗组治愈率和有效率分别为50.00%和76.67%,症状治疗组治愈率和有效率分别为23.33%和66.67%,两组治愈率有统计学差异,但有效率无统计学差异.疗程治疗组8例出现不良反应,对照组6例出现不良反应,均可耐受.结论:卡泊三醇治疗轻中度斑块状银屑病应足疗程用药.     

钙泊三醇倍他米松软膏外用治疗寻常性银屑病的随机、双盲、对照研究

目的 探讨钙泊三醇倍他米松软膏外用治疗稳定期寻常性银屑病患者的临床疗效和安全性。方法 随机、双盲、阳性药物平行对照、多中心临床试验,入组320例寻常性银屑病患者,随机纳入试验组或对照组,疗程4周。试验组早晨外用模拟剂软膏基质,晚间外用钙泊三醇倍他米松软膏;对照组早晚单用卡泊三醇软膏。于首次用药后第1、2、4周观察临床疗效及安全性。结果 治疗4周后试验组PASI评分较基线下降百分比（79.23%）大于对照组（70.43%）,两组比较,P < 0.01;且在治疗1周后的疗效优于对照组。治疗4周后,PASI评分较基线下降≥75%的患者频数百分比比较,试验组有效率为73.03%,对照组为48.32%,P < 0.01,两组差异有统计学意义。治疗1、2、4周后试验组靶皮损红斑、浸润、鳞屑单独积分以及皮损总面积百分比等指标改善方面均优于对照组。320例受试者中不良事件发生率为18.1%,不良反应发生率为13.1%,两组间差异无统计学意义。药物不良反应主要为与皮肤有关的轻中度反应如瘙痒、毛囊炎、红斑等。结论 钙泊三醇倍他米松软膏治疗稳定期寻常性银屑病患者具有起效快、疗效好和用药方便、相对安全的特点。     

得肤宝联合敏泊斯皮肤修护精华乳治疗轻中度寻常型银屑病疗效观察

目的 观察卡泊三醇倍他米松软膏（得肤宝）联合皮肤修护精华乳治疗轻中度寻常型银屑病的临床疗效。方法 选取2021年9月—12月在皮肤科收治的117例轻中度寻常型银屑病患者,按照随机数字表法分为对照组57组,试验组60例,对照组皮损处外涂卡泊三醇倍他米松软膏1次/d;试验组在外用卡泊三醇倍他米松软膏1 h后,外涂敏泊斯皮肤修护精华乳,1次/d;疗程4周,每2周随访1次进行疗效比较。结果 2组患者治疗2周、4周后皮损面积、红斑、浸润、鳞屑评分及银屑病皮损面积和严重程度指数（PASI）评分、瘙痒程度评分均较治疗前下降,且试验组各项评分均低于对照组,差异有统计学意义（P<0.05）。结论 卡泊三醇倍他米松软膏联合皮肤修护精华乳治疗轻中度寻常型银屑病疗效显著,优于单用卡泊三醇倍他米松软膏。     

钙泊三醇倍他米松软膏联合卡泊三醇软膏序贯治疗寻常型银屑病疗效评价

目的：评价钙泊三醇倍他米松软膏联合卡泊三醇软膏治疗寻常型银屑病的临床疗效。方法：30例银屑病患者全身左右侧皮损随机分为治疗组或对照组。治疗组外用钙泊三醇倍他米松软膏和卡泊三醇软膏;对照组外用卡泊三醇软膏。治疗第2、4、8周末进行疗效评价。结果：治疗2、4、8周后治疗组有效率（53.33%、70%和86.67%）均明显高于对照组（30%、46.67%和66.67%）,组间差异均有统计学意义（P〈0.05）。结论：钙泊三醇倍他米松软膏联合卡泊三醇软膏治疗寻常型银屑病疗效较单独使用卡泊三醇好。     

Tacrolimus ointment improves psoriasis in a microplaque assay

Tacrolimus (FK506) is an effective and well tolerated immunosuppressant used to prevent allograft rejection. We describe the evaluation of two tacrolimus ointment formulations for treatment of chronic plaque-type psoriasis. This was a microplaque assay with randomized, double-blind design. Sixteen patients (15 men, one woman, all white and 28-69 years old) with chronic plaque-type psoriasis participated. Six different ointments were applied to discrete microplaques, 17 mm in diameter, on a descaled psoriasis lesion: these were tacrolimus ointment with diisopropyl adipate as penetration enhancer, tacrolimus ointment without diisopropyl adipate, 0.1% betamethasone 17alpha-valerate ointment, 0.005% calcipotriol ointment and, as controls, the ointment bases for tacrolimus and betamethasone. Ointments were reapplied and the area was sealed every 2-3 days during the 14-day treatment period. After 7 and 14 days, erythema and infiltration were graded on a scale of 0-4, and superficial blood flow was measured with a laser Doppler flowmeter. Epidermal thickness was measured histologically at the end of treatment. Compared with the vehicle controls, sites treated with tacrolimus ointment (with or without penetration enhancer) showed a significant reduction in erythema and infiltration (P < 0. 001), a significant reduction in superficial blood flow (P < 0.01) and a significant decrease in epidermal thickness (P < or = 0.001). Results for betamethasone and calcipotriol, when compared with the vehicle controls, were similar. These results suggest that, under conditions of descaling and occlusion, tacrolimus ointment is effective in the treatment of psoriasis.     

Tratamiento de la psoriasis en placas con propiltiouracilo tópico

—Background: in recent years there are several reports that show the efficacy of both oral and topical antithyroid drugs (propylthiouracil and methimazole) in the treatment of plaque-type psoriasis.Objective: to determine the efficacy of topical propylthiouracil (5% cream) in comparison with calcipotriol ointment in the treatment of patients with plaque-type psoriasis.Materials and methods: a prospective, randomized comparison of calcipotriol ointment (14 patients) and propylthiouracil 5% cream (14 patients) was carried out.Results: there were no statistically differences between the PASI scores at 4 and 8 week from baseline in the group of patients treated with topical propylthiouracil. The differences in the PASI scores from baseline were statistically significantly in favour of calcipotriol.Conclusions: topical propylthiouracil is not an effective therapy in patients with plaque-type psoriasis.     

An Open Label Prospective Randomized Trial to Compare the Efficacy of Coal Tar-Salicylic Acid Ointment Versus Calcipotriol/Betamethasone Dipropionate Ointment in the Treatment of Limited Chronic Plaque Psoriasis

Background:Chronic plaque psoriasis is a common papulosquamous skin disorder, for which a number of topical agents are being used including coal tar, topical steroids and more recently topical calcipotriol/betamethasone dipropionate. There is no study comparing purified coal tar preparation with calcipotriol/betamethasone dipropionate ointment in limited chronic plaque psoriasis.Results:Mean PASI was significantly lower at week 2 (P = 0.01) and week 4 follow-up (P = 0.05) and the mean reduction in PASI was significantly higher at week 2 (P = 0.02) with calcipotriol/betamethasone than coal tar-salicylic acid, but this difference was not sustained at subsequent follow-up visits. Similarly, PGA scores at weeks 2 and 4 were significantly lower with calcipotriol/betamethasone dipropionate ointment (P = 0.003 and P = 0.007 respectively). There was no significant difference in any parameter during subsequent follow-up visits or at the end of the treatment phase (12 weeks).Conclusion:Topical nightly application of calcipotriol/betamethasone dipropionate ointment leads to an initial, more rapid reduction in disease severity, but the overall outcome parameters are comparable in the two treatment groups.     

308nm准分子激光联合卡泊三醇软膏治疗斑块状银屑病疗效评价

目的：评价308 nm准分子激光联合卡泊三醇软膏治疗斑块状银屑病的临床疗效.方法：将93例稳定期斑块状银屑病随机分为3组,治疗组（33例） 予308 nm准分子激光照射,每周2次联合外搽卡泊三醇软膏,每日2次;对照1组（30例）外搽卡泊三醇软膏;对照2组（30例）,予308 nm准分子激光照射,方法同治疗组,2个月后判断疗效.结果：治疗组、对照1组和对照2组的有效率分别为90.91%、73.33%、63.33%.3组间疗效比较差异有统计学意义（均P〈0.05）.结论：308 nm准分子激光联合卡泊三醇软膏治疗斑块状银屑病能更好地提高疗效.     

A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris

In this study, we compared a new combination ointment containing both calcipotriol and betamethasone dipropionate with betamethasone dipropionate ointment (Diprosone) and calcipotriol ointment (Daivonex) in patients with psoriasis vulgaris; 1106 patients were randomized to twice daily double-blind treatment with combination, betamethasone dipropionate or calcipotriol for 4 weeks. Patients then received twice daily calcipotriol, unblinded, for a further 4 weeks. Mean percentage change in PASI at end of the double-blind phase was -74.4 (combination group), -61.3 (betamethasone group) and -55.3 (calcipotriol group). Mean difference (95% Cl) combination-betamethasone was -13.1 (-16.9 to -9.3, p < 0.001) and for combination-calcipotriol -19.0 (-22.8 to -15.2, p <0.001). The differences in PASI were also statistically significant after 1 week. In the double-blind phase, 8.1% of patients (combination) reported lesional/ perilesional adverse reactions compared to 4.7% (betamethasone) and 12.0% (calcipotriol). In the combination group, mean PASI at the end of the double-blind phase was 2.5, and at end of the unblinded phase 3.6, compared with 3.9 and 4.1 (betamethasone) and 4.4 and 3.7 (calcipotriol). Calcipotriol/betamethasone combination is more effective and has a more rapid onset of action than either active constituent used alone, and is well tolerated. It is safe to transfer patients from combination to calcipotriol, with maintenance of clinical effect.     

百癣夏塔热片联合窄波UVB治疗寻常型银屑病疗效评价

目的:评价百癣夏塔热片联合窄波UVB治疗寻常型银屑病的疗效。方法:87例患者随机分为2组,治疗组(42例)采用百癣夏塔热片联合窄波UVB治疗,对照组(45例)仅窄波UVB照射,两组均外擦醋酸曲安尿素软膏,疗程均为8周。结果:两组有效率分别为92.9%和77.8%,差异有显著性(P0.05)。结论:百癣夏塔热片联合窄波UVB治疗寻常型银屑病有效。